

Twist Bioscience to Present at the 37th Annual J.P. Morgan Healthcare Conference

January 2, 2019

SAN FRANCISCO--(BUSINESS WIRE)-Jan. 2, 2019 - Twist Bioscience Coporation (NASDAC: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday. January 1997. The Annual J.P. Morgan Healthcare Conference on the Conference on

This presentation will be webcast live and can be accessed by visiting the "Presentations" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 90 days following the conclusion of the live even

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for nex-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including high-terminal, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005162/er

Source: Twist Bioscience Corporation

Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com

Media Contact: Angela Bitting 925- 202-6211